New Anti-Blindness Drug
In the past, treatments for age-related macular degeneration, the leading cause of blindness in those over 60 in the United States, were limited to slowing down the progression of the disease. Now a new drug, just submitted for approval to the Food and Drug Administration, shows hope of actually restoring lost vision in a substantial number of patients.
At a meeting on January 14 for specialists in the disease, San Francisco-based Genentech, which developed the drug, will release detailed data from a late-stage clinical trial. Preliminary data from that trial show it is in line with an earlier study – in both, 95% of the patients who received the drug showed either stabilized or improved vision. In the earlier study, the vision for over one-third of those who received the higher of two doses of the drug improved by three lines on an eye chart – many of them to the point that they could pass an eye exam for a driver’s license. (Details about visual improvement from the more recent study are scheduled to be announced at the meeting.)
[Click here to view the effects of common eye diseases.]
According to Emily Chew, Deputy Director of the Division of Epidemiology and Clinical Research at the National Eye Institute (NEI), which is part of the National Institutes of Health, “This is the first time we actually see vision improvement, and it’s not an insignificant number. [It] is quite remarkable.”
Dawn Kalmar, a Genentech spokesperson, says the company has asked the FDA for a “priority review,” which would mean a six-month review time period instead of 10 months. To bridge the gap until approval, the company is making the treatment available through a 5,000-person study in which all the participants will receive the drug. Kalmar says it will be administered at more than one hundred sites throughout the country.
Called Lucentis, the drug works by blocking the growth of new blood vessels that leak blood and other fluids into the retina, causing vision loss in the less common but most severe “wet” form of the disease. Lucentis is a modified version of another drug by Genentech, called Avastin, which is a monoclonal antibody that binds to a protein involved in stimulating new blood vessel growth, or angiogenesis. Avastin is the first anti-angiogenesis drug to be approved for cancer treatment, according to the company. Lucentis is a version of a related antibody molecule that is shortened, making it capable of penetrating the retina.*
Although Avastin is not approved by the FDA for treating macular degeneration, it “has been used by a lot of ophthalmologists who are anxious to put something in the eye,” director Chew says. “[It has] quite a following, but on the other hand we don’t have enough information on toxicity and whether it really does anything. A number of investigators are trying to design a trial to see if Avastin is effective or not.”
The cause of macular degeneration is still unclear, and treatments are limited. Macugen, developed by Eyetech, New York, NY, was approved by FDA at the end of 2004. While it also blocks new vessel growth, it has not been shown to improve vision. Preliminary research is also underway by more than one group on combining drugs such as Lucentis with photodynamic therapy, in which a laser activates a drug that destroys new blood vessels.
Currently, Lucentis does have a drawback: the drug must be injected directly into the eye on a monthly basis. Trials now underway will establish if it can be administered less frequently.
The current version of Lucentis, however, represents a major breakthrough. While earlier treatments were “better than nothing at all,” according to Chew at the National Eye Institute, Lucentis is creating “a lot of excitement.”
*Correction: The original version of this sentence could have been read to mean Lucentis is simply shortened Avastin. In fact, it is an antibody fragment of a full-length anti-angiogenesis antibody, but is not a fragment of Avastin.
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
ChatGPT is going to change education, not destroy it
The narrative around cheating students doesn’t tell the whole story. Meet the teachers who think generative AI could actually make learning better.
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.